Please download the dossier by clicking on the dossier button x
×

Methods comprising desmopressin

  • US 10,137,167 B2
  • Filed: 12/30/2013
  • Issued: 11/27/2018
  • Est. Priority Date: 05/21/2008
  • Status: Active Grant
First Claim
Patent Images

1. A method of further reducing nocturnal voids in a male patient in need thereof comprising:

  • measuring the patient'"'"'s serum sodium level;

    administering to the patient, with a serum sodium level of at least 130 mmol/L, prior to bedtime an orodispersible dose of desmopressin chosen from 25 μ

    g, 50 μ

    g, and 100 μ

    g over a first treatment period of about 28 days, wherein the dose is taken from 0.8 to 3 hours prior to the patient'"'"'s bedtime and once daily;

    measuring the patient'"'"'s serum sodium level after the first treatment period; and

    continuing to administer the orodisperible dose of desmopressin prior to bedtime over a second contiguous treatment period of at least 28 days to about 1 year if the male patient has a serum sodium level of at least 130 mmol/L,wherein the nocturnal voids over the second treatment period are further reduced in view of the reduction in the nocturnal voids over the first treatment period and wherein the reduction in the nocturnal voids over the first treatment period is determined based on the patient'"'"'s nocturnal voids before administration of the orodispersible dose of desmopressin for the first treatment period.

View all claims
  • 1 Assignment
Timeline View
Assignment View
    ×
    ×